In a report released today, Jason Gerberry from Merrill Lynch maintained a Sell rating on Teva Pharmaceutical Industries (TEVA), with a price target of $7.00. The company’s shares closed last Monday at $7.68, close to its 52-week low of $6.07.
According to TipRanks.com, Gerberry has currently no stars on a ranking scale of 0-5 stars, with an average return of -7.2% and a 37.9% success rate. Gerberry covers the Healthcare sector, focusing on stocks such as Ionis Pharmaceuticals, Horizon Therapeutics, and Jazz Pharmaceuticals.
Currently, the analyst consensus on Teva Pharmaceutical Industries is a Hold with an average price target of $12.40.
See today’s analyst top recommended stocks >>
Based on Teva Pharmaceutical Industries’ latest earnings release for the quarter ending December 31, the company reported a quarterly net profit of $110 million. In comparison, last year the company had a GAAP net loss of $2.87 billion.
Based on the recent corporate insider activity of 48 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of TEVA in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Teva Pharmaceutical Industries Ltd. engages in the development and production of medicines. Its products include medicines for cardiovascular diseases, pain relievers, obesity, cancer and supportive care, infectious diseases and human immunodeficiency viruses, and colds and coughs. The company was founded in 1901 and is headquartered in Petah Tikva, Israel.
